FDA OKs sebetralstat, now Ekterly, as oral on-demand HAE therapy
The U.S. Food and Drug Administration (FDA) has approved sebetralstat for the on-demand treatment of swelling attacks in adults and children, ages 12 and older, with hereditary angioedema (HAE), its developer Kalvista Pharmaceuticals announced. Sebetralstat will be sold under the brand name Ekterly, and is the first…